Ronald Mann, Justices poised to protect generics manufacturers from liability for decisions of pharmacists about prescribing ...
The justices are set to hear Hikma v. Amarin, a battle over drug patents that could raise costs for patients and change the ...
The availability of generic drugs is expected to have a positive impact in Canada, including potential cost savings for ...
Money Digest on MSN
Why are generic medications so cheap and where are they made?
If you've had a prescription lately, chances are good it was part of the 91% of U.S. drugs that are considered generic. So, ...
Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.
MedPage Today on MSN
SCOTUS Grapples With Marketing of Vascepa Generic With 'Skinny Label'
Can a generic manufacturer compare its product to the branded competitor?
By Bhanvi Satija and Marleen Kaesebier LONDON, April 28 (Reuters) - Novartis posted first-quarter core operating profit and ...
Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...
By Siddhi Mahatole April 29 (Reuters) - Teva Pharmaceutical beat first-quarter profit estimates on Wednesday as growth in its ...
Amneal leans on generics stability, biosimilar launches, and Crexont growth as 2026 guidance points to higher EBITDA and EPS despite Specialty headwinds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results